+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cellular Immunotherapy Market Size, Share & Trends Analysis Report by Therapy Type (CAR T Cell Therapy, Dendritic Cell Therapy), by Indication (B-cell Malignancies, Prostate Cancer), by End-use, by Region, and Segment Forecasts, 2022-2030

  • PDF Icon

    Report

  • 165 Pages
  • July 2022
  • Region: Global
  • Grand View Research
  • ID: 5644984
Description Jump to:
The global cellular immunotherapy market size is expected to reach USD 37.97 billion by 2030. It is estimated to register a CAGR of 22.41% during the forecast period, driven by the growing government support for innovative therapies research, rising prevalence of cancer, development of advanced cell-based immunotherapies, and increasing R&D investment by global players.

Growing support from government organizations and research institutes including the National Cancer Institute (NCI) and Center of Excellence in Immunology (CEI) for cellular immunotherapies research is one of the major factors driving the market growth. For instance, the CEI pulls out experts from other institutes such as NCI and NIH to promote the growth of immunotherapy for the treatment of cancer. Also, the Surgery Branch of the National Cancer Institute's Center for Cancer Research (CCR) is committed to the innovation of novel immunotherapies for the treatment of cancer patients.

The rising number of M&As, collaborations, acquisitions, and funding is a major trend observed in the market. M&A and collaboration help companies expand their existing product portfolio and regional reach in a short period. For instance, in March 2021, TrakCel received funding from Labcorp and AmerisourceBergen for cellular therapy orchestration research and global expansion. Also, in April 2020, Kite (a Gilead Company) and Teneobio, Inc. entered into a license agreement through which Kite will receive exclusive rights to specific antibodies targeted to B-cell maturation antigen (BCMA). Thus, such M&A and collaborations are expected to boost the market growth.

A substantial number of cellular immunotherapy companies are engaged in new product launches, pertaining to licensing, collaborations, & acquisitions, and regional expansion. Some of the key companies in the market are Bristol-Myers Squibb Company; Novartis AG; Gilead Sciences Inc. (Kite Pharma); F. Hoffmann-La Roche Ltd.; and Johnson & Johnson. These companies are adopting various business models to gain a competitive advantage. For instance, in February 2021, Novartis secured approval for the first Australian commercial CAR-T manufacturing site for Kymriah. With this approval, the company would be able to develop Kymriah in Australia, thereby providing easy access to Australian patients.

The COVID-19 pandemic has had a high impact on the market. Owing to stringent regulations to curb the pandemic, a slowdown in clinical trials, approval of new drugs, and delayed cancer diagnosis have been observed, affecting the industry's growth amid the pandemic. However, in several countries, the effect of COVID-19 declined after the third quarter of 2021, which helped the market regain traction.

Cellular Immunotherapy Market Report Highlights

  • CAR T cell therapy segment contributed a significant revenue share of 71.6% in 2021. Factors such as approval of new drugs, patent protection, and a robust product pipeline are expected to drive the segment
  • B-cell malignancy is the largest segment by indication in 2021 due to the high product penetration; BREYANZI and Yescarta are among the drugs that contribute to its high share
  • Hospitals dominated the market in 2021 due to the availability of skilled healthcare practitioners in hospital settings and ease of reimbursement
  • North America dominated the market in terms of revenue in 2021, owing to the availability of a well-established healthcare infrastructure, high per capita healthcare expenditure, and the increasing prevalence of cancer in the region
  • Some of the key players in the market space are Gilead Sciences Inc. (Kite Pharma); Bristol-Myers Squibb Company; Novartis AG; F. Hoffmann-La Roche Ltd.; GlaxoSmithKline plc.; Merck KGaA; AstraZeneca; Celyad; Pfizer Inc.; Adicet Bio, Inc.; Johnson & Johnson; and Dendreon Pharmaceuticals LLC

Table of Contents

Chapter 1. Methodology and Scope
1.1 Market Segmentation
1.1.1 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.3.6 List of primary sources
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity flow analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country-wise market estimation using a bottom-up approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Abbreviations
1.11 Objectives
1.11.1 Objective 1
1.11.2 Objective 2
1.11.3 Objective 3
1.11.4 Objective 4
Chapter 2. Executive Summary
2.1 Market Summary
Chapter 3. Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.2 Regulatory framework
3.3 Penetration and Growth Prospect Mapping
3.4 Pipeline Analysis
3.5 Market Dynamics
3.5.1 Market driver analysis
3.5.2 Market restraint analysis
3.6 PESTEL Analysis
Chapter 4. Global Cellular Immunotherapy Market - Segment Analysis, By Therapy Type, 2018 - 2030 (USD Million)
4.1 Global Cellular Immunotherapy Market: Therapy Type Movement Analysis
4.2 CAR T Cell Therapy
4.2.1 CAR T Cell Therapy market estimates and forecast, 2018 - 2030 (USD Million)
4.3 Dendritic Cell Therapy
4.3.1 Dendritic Cell Therapy market estimates and forecast, 2018 - 2030 (USD Million)
4.4 NK Cell Therapy
4.4.1 TIL Therapy market estimates and forecast, 2018 - 2030 (USD Million)
4.5 Others
4.5.1 Other market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 5. Global Cellular Immunotherapy Market - Segment Analysis, by Indication, 2018 - 2030 (USD Million)
5.1 Global Cellular Immunotherapy Market: Indication Movement Analysis
5.2 B-cell Malignancies
5.2.1 B-cell Malignancies market estimates and forecast, 2018 - 2030 (USD Million)
5.3 Prostate Cancer
5.3.1 Prostate Cancer market estimates and forecast, 2018 - 2030 (USD Million)
5.4 Liver Cancer
5.4.1 Liver Cancer market estimates and forecast, 2018 - 2030 (USD Million)
5.5 Renal Cell Carcinoma
5.5.1 Renal Cell Carcinoma market estimates and forecast, 2018 - 2030 (USD Million)
5.6 Others
5.6.1 Other market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 6. Global Cellular Immunotherapy Market - Segment Analysis, By End Use, 2018 - 2030 (USD Million)
6.1 Global Cellular Immunotherapy Market: End Use Movement Analysis
6.2 Hospitals
6.2.1 Hospital market estimates and forecast, 2018 - 2030 (USD Million)
6.3 Cancer Institutes
6.3.1 Cancer institute’s market estimates and forecast, 2018 - 2030 (USD Million)
6.4 Others
6.4.1 Other market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 7. Cellular Immunotherapy Market: Segment Analysis, by Region, 2018 - 2030 (USD Million)
7.1 Cellular Immunotherapy Market: Regional Movement Analysis
7.1.1 North America
7.1.1.1 North America market estimates and forecast, 2018 - 2030 USD Million
7.1.1.2 U.S.
7.1.1.2.1 U.S. market estimates and forecast, 2018 - 2030 USD Million
7.1.1.3 Canada
7.1.1.3.1 Canada market estimates and forecast, 2018 - 2030 USD Million
7.1.2 Europe
7.1.2.1 Europe market estimates and forecast, 2018 - 2030 USD Million
7.1.2.2 U.K.
7.1.2.2.1 U.K. market estimates and forecast, 2018 - 2030 USD Million
7.1.2.3 Germany
7.1.2.3.1 Germany market estimates and forecast, 2018 - 2030 USD Million
7.1.2.4 France
7.1.2.4.1 France market estimates and forecast, 2018 - 2030 USD Million
7.1.2.5 Spain
7.1.2.5.1 Spain market estimates and forecast, 2018 - 2030 USD Million
7.1.2.6 Italy
7.1.2.6.1 Italy market estimates and forecast, 2018 - 2030 USD Million
7.1.2.7 Russia
7.1.2.7.1 Russia market estimates and forecast, 2018 - 2030 USD Million
7.1.3 Asia Pacific
7.1.3.1 Asia Pacific market estimates and forecast, 2018 - 2030 USD Million
7.1.3.2 Japan
7.1.3.2.1 Japan market estimates and forecast, 2018 - 2030 USD Million
7.1.3.3 China
7.1.3.3.1 China market estimates and forecast, 2018 - 2030 USD Million
7.1.3.4 India
7.1.3.4.1 India market estimates and forecast, 2018 - 2030 USD Million
7.1.3.5 Australia
7.1.3.5.1 Australia market estimates and forecast, 2018 - 2030 USD Million
7.1.3.5 South Korea
7.1.3.5.1 South Korea market estimates and forecast, 2018 - 2030 USD Million
7.1.4 Latin America
7.1.4.1 Latin America market estimates and forecast, 2018 - 2030 USD Million
7.1.4.2 Brazil
7.1.4.2.1 Brazil market estimates and forecast, 2018 - 2030 USD Million
7.1.4.3 Mexico
7.1.4.3.1 Mexico market estimates and forecast, 2018 - 2030 USD Million
7.1.4.4 Argentina
7.1.4.4.1 Argentina market estimates and forecast, 2018 - 2030 USD Million
7.1.5 Middle East & Africa
7.1.5.1 Middle East & Africa market estimates and forecast, 2018 - 2030 USD Million
7.1.5.2 South Africa
7.1.5.2.1 South Africa market estimates and forecast, 2018 - 2030 USD Million
7.1.5.3 Saudi Arabia
7.1.5.3.1 Saudi Arabia market estimates and forecast, 2018 - 2030 USD Million
7.1.5.5 United Arab Emirates
7.1.5.5.1 United Arab Emirates market estimates and forecast, 2018 - 2030 USD Million
Chapter 8. Global Cellular Immunotherapy Market: Competitive Analysis
8.1 Recent Developments and Impact Analysis, by Key Market Participants
8.1.1 Synergy analysis: Major deals and strategic alliances
8.1.1.1 New Product Launches
8.1.1.2 Mergers and Acquisitions
8.1.1.3 Partnerships & Agreements
8.2 Company Categorization
8.2.1 Innovators
8.2.2 Market Leaders
8.2.3 Emerging Players
8.2.4 Heat Map Analysis
8.3 Company Market Position Analysis
8.4 Vendor Landscape
8.4.1 List of Key Distributors and Channel Partners
8.4.2 List of Potential End Users
8.4.3 Key Company Market Share Analysis, 2021
8.5 Company Market Share/Ranking, 2021
8.5.1 Competitive Dashboard Analysis
8.6 Private Companies
8.6.1 List of Key Emerging Companies
8.6.2 Regional Network Map
8.7 Company Profiles
8.7.1 Bristol-Myers Squibb Company
8.7.1.1 Company overview
8.7.1.2 Financial performance
8.7.1.3 Product benchmarking
8.7.1.4 Strategic initiatives
8.7.2 F. Hoffmann-La Roche Ltd.
8.7.2.1 Company overview
8.7.2.2 Financial performance
8.7.2.3 Product benchmarking
8.7.2.4 Strategic initiatives
8.7.3 Merck KGaA
8.7.3.1 Company overview
8.7.3.2 Financial performance
8.7.3.3 Product benchmarking
8.7.3.4 Strategic initiatives
8.7.4 GlaxoSmithKline plc.
8.7.4.1 Company overview
8.7.4.2 Financial performance
8.7.4.3 Product benchmarking
8.7.4.4 Strategic initiatives
8.7.5 AstraZeneca
8.7.5.1 Company overview
8.7.5.2 Financial performance
8.7.5.3 Product benchmarking
8.7.5.4 Strategic initiatives
8.7.6 Pfizer Inc.
8.7.6.1 Company overview
8.7.6.2 Product benchmarking
8.7.6.3 Strategic initiatives
8.7.7 Gilead Sciences Inc. (Kite Pharma)
8.7.7.1 Company overview
8.7.7.2 Financial performance
8.7.7.3 Product benchmarking
8.7.8 Dendreon Pharmaceuticals LLC
8.7.8.1 Company overview
8.7.8.2 Financial performance
8.7.8.3 Product benchmarking
8.7.8.4 Strategic initiatives
8.7.9 Novartis AG
8.7.9.1 Company overview
8.7.9.2 Financial performance
8.7.9.3 Product benchmarking
8.7.9.4 Strategic initiatives
8.7.10 Celyad
8.7.10.1 Company overview
8.7.10.2 Financial performance
8.7.10.3 Product benchmarking
8.7.10.4 Strategic initiatives
8.7.11 Adicet Bio, Inc.
8.7.11.1 Company overview
8.7.11.2 Financial performance
8.7.11.3 Product benchmarking
8.7.11.4 Strategic initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 Global Cellular Immunotherapy Market, By Region, 2018-2030 (USD Million)
Table 4 Global Cellular Immunotherapy Market, By Therapy, 2018-2030 (USD Million)
Table 5 Global Cellular Immunotherapy Market, By Indication, 2018-2030 (USD Million)
Table 6 Global Cellular Immunotherapy Market, By End Use, 2018-2030 (USD Million)
Table 7 North America Cellular Immunotherapy Market, By Region, 2018-2030 (USD Million)
Table 8 North America Cellular Immunotherapy Market, By Therapy, 2018-2030 (USD Million)
Table 9 North America Cellular Immunotherapy Market, By Indication, 2018-2030 (USD Million)
Table 10 North America Cellular Immunotherapy Market, By End Use, 2018-2030 (USD Million)
Table 11 U.S. Cellular Immunotherapy Market, By Therapy, 2018-2030 (USD Million)
Table 12 U.S. Cellular Immunotherapy Market, By Indication, 2018-2030 (USD Million)
Table 13 U.S. Cellular Immunotherapy Market, By End Use, 2018-2030 (USD Million)
Table 14 Canada Cellular Immunotherapy Market, By Therapy, 2018-2030 (USD Million)
Table 15 Canada Cellular Immunotherapy Market, By Indication, 2018-2030 (USD Million)
Table 16 Canada Cellular Immunotherapy Market, By End Use, 2018-2030 (USD Million)
Table 17 Europe Cellular Immunotherapy Market, By Region, 2018-2030 (USD Million)
Table 18 Europe Cellular Immunotherapy Market, By Therapy, 2018-2030 (USD Million)
Table 19 Europe Cellular Immunotherapy Market, By Indication, 2018-2030 (USD Million)
Table 20 Europe Cellular Immunotherapy Market, By End Use, 2018-2030 (USD Million)
Table 21 Germany Cellular Immunotherapy Market, By Therapy, 2018-2030 (USD Million)
Table 22 Germany Cellular Immunotherapy Market, By Indication, 2018-2030 (USD Million)
Table 23 Germany Cellular Immunotherapy Market, By End Use, 2018-2030 (USD Million)
Table 24 U.K. Cellular Immunotherapy Market, By Therapy, 2018-2030 (USD Million)
Table 25 U.K. Cellular Immunotherapy Market, By Indication, 2018-2030 (USD Million)
Table 26 U.K. Cellular Immunotherapy Market, By End Use, 2018-2030 (USD Million)
Table 27 France Cellular Immunotherapy Market, By Therapy, 2018-2030 (USD Million)
Table 28 France Cellular Immunotherapy Market, By Indication, 2018-2030 (USD Million)
Table 29 France Cellular Immunotherapy Market, By End Use, 2018-2030 (USD Million)
Table 30 Italy Cellular Immunotherapy Market, By Therapy, 2018-2030 (USD Million)
Table 31 Italy Cellular Immunotherapy Market, By Indication, 2018-2030 (USD Million)
Table 32 Italy Cellular Immunotherapy Market, By End Use, 2018-2030 (USD Million)
Table 33 Spain Cellular Immunotherapy Market, By Therapy, 2018-2030 (USD Million)
Table 34 Spain Cellular Immunotherapy Market, By Indication, 2018-2030 (USD Million)
Table 35 Spain Cellular Immunotherapy Market, By End Use, 2018-2030 (USD Million)
Table 36 Russia Cellular Immunotherapy Market, By Therapy, 2018-2030 (USD Million)
Table 37 Russia Cellular Immunotherapy Market, By Indication, 2018-2030 (USD Million)
Table 38 Russia Cellular Immunotherapy Market, By End Use, 2018-2030 (USD Million)
Table 39 Asia Pacific Cellular Immunotherapy Market, By Region, 2018-2030 (USD Million)
Table 40 Asia Pacific Cellular Immunotherapy Market, By Therapy, 2018-2030 (USD Million)
Table 41 Asia Pacific Cellular Immunotherapy Market, By Indication, 2018-2030 (USD Million)
Table 42 Asia Pacific Cellular Immunotherapy Market, By End Use, 2018-2030 (USD Million)
Table 43 Japan Cellular Immunotherapy Market, By Therapy, 2018-2030 (USD Million)
Table 44 Japan Cellular Immunotherapy Market, By Indication, 2018-2030 (USD Million)
Table 45 Japan Cellular Immunotherapy Market, By End Use, 2018-2030 (USD Million)
Table 46 China Cellular Immunotherapy Market, By Therapy, 2018-2030 (USD Million)
Table 47 China Cellular Immunotherapy Market, By Indication, 2018-2030 (USD Million)
Table 48 China Cellular Immunotherapy Market, By End Use, 2018-2030 (USD Million)
Table 49 India Cellular Immunotherapy Market, By Therapy, 2018-2030 (USD Million)
Table 50 India Cellular Immunotherapy Market, By Indication, 2018-2030 (USD Million)
Table 51 India Cellular Immunotherapy Market, By End Use, 2018-2030 (USD Million)
Table 52 South Korea Cellular Immunotherapy Market, By Therapy, 2018-2030 (USD Million)
Table 53 South Korea Cellular Immunotherapy Market, By Indication, 2018-2030 (USD Million)
Table 54 South Korea Cellular Immunotherapy Market, By End Use, 2018-2030 (USD Million)
Table 55 Australia Cellular Immunotherapy Market, By Therapy, 2018-2030 (USD Million)
Table 56 Australia Cellular Immunotherapy Market, By Indication, 2018-2030 (USD Million)
Table 57 Australia Cellular Immunotherapy Market, By End Use, 2018-2030 (USD Million)
Table 58 Latin America Cellular Immunotherapy Market, By Region, 2018-2030 (USD Million)
Table 59 Latin America Cellular Immunotherapy Market, By Therapy, 2018-2030 (USD Million)
Table 60 Latin America Cellular Immunotherapy Market, By Indication, 2018-2030 (USD Million)
Table 61 Latin America Cellular Immunotherapy Market, By End Use, 2018-2030 (USD Million)
Table 62 Brazil Cellular Immunotherapy Market, By Therapy, 2018-2030 (USD Million)
Table 63 Brazil Cellular Immunotherapy Market, By Indication, 2018-2030 (USD Million)
Table 64 Brazil Cellular Immunotherapy Market, By End Use, 2018-2030 (USD Million)
Table 65 Mexico Cellular Immunotherapy Market, By Therapy, 2018-2030 (USD Million)
Table 66 Mexico Cellular Immunotherapy Market, By Indication, 2018-2030 (USD Million)
Table 67 Mexico Cellular Immunotherapy Market, By End Use, 2018-2030 (USD Million)
Table 68 Argentina Cellular Immunotherapy Market, By Therapy, 2018-2030 (USD Million)
Table 69 Argentina Cellular Immunotherapy Market, By Indication, 2018-2030 (USD Million)
Table 70 Argentina Cellular Immunotherapy Market, By End Use, 2018-2030 (USD Million)
Table 71 Middle East & Africa Cellular Immunotherapy Market, By Region, 2018-2030 (USD Million)
Table 72 Middle East & Africa Cellular Immunotherapy Market, By Therapy, 2018-2030 (USD Million)
Table 73 Middle East & Africa Cellular Immunotherapy Market, By Indication, 2018-2030 (USD Million)
Table 74 Middle East & Africa Cellular Immunotherapy Market, By End Use, 2018-2030 (USD Million)
Table 75 Saudi Arabia Cellular Immunotherapy Market, By Therapy, 2018-2030 (USD Million)
Table 76 Saudi Arabia Cellular Immunotherapy Market, By Indication, 2018-2030 (USD Million)
Table 77 Saudi Arabia Cellular Immunotherapy Market, By End Use, 2018-2030 (USD Million)
Table 78 South Africa Cellular Immunotherapy Market, By Therapy, 2018-2030 (USD Million)
Table 79 South Africa Cellular Immunotherapy Market, By Indication, 2018-2030 (USD Million)
Table 80 South Africa Cellular Immunotherapy Market, By End Use, 2018-2030 (USD Million)
Table 81 UAE Cellular Immunotherapy Market, By Therapy, 2018-2030 (USD Million)
Table 82 UAE Cellular Immunotherapy Market, By Indication, 2018-2030 (USD Million)
Table 83 UAE Cellular Immunotherapy Market, By End Use, 2018-2030 (USD Million)
List of Figures
Fig. 1 Cellular Immunotherapy market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Cellular immunotherapy market snapshot
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook, revenue, 2021, (USD Million)
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Cellular immunotherapy market driver impact
Fig. 14 Cellular immunotherapy market restraint impact
Fig. 15 SWOT analysis, by factor (political & legal, economic, and technological)
Fig. 16 Industry Analysis-Porter’s
Fig. 17 Strategy mapping
Fig. 18 Cellular immunotherapy market: therapy class outlook and key takeaways
Fig. 19 Cellular immunotherapy market: therapy class movement analysis & market share 2021 & 2030
Fig. 20 CAR T cell therapy cellular immunotherapy market estimates and forecast, 2018-2030 (USD Million)
Fig. 21 Dendritic cell therapy cellular immunotherapy market estimates and forecast, 2018-2030 (USD Million)
Fig. 22 NK cell therapy cellular immunotherapy market estimates and forecast, 2018-2030 (USD Million)
Fig. 23 TIL therapy cellular immunotherapy market estimates and forecast, 2018-2030 (USD Million)
Fig. 24 Others cellular immunotherapy market estimates and forecast, 2018-2030 (USD Million)
Fig. 25 Cellular immunotherapy market: Indication outlook and key takeaways
Fig. 26 Cellular immunotherapy market: Indication movement analysis & market share 2021 & 2030
Fig. 27 B-cell malignancies market estimates and forecast, 2018-2030 (USD Million)
Fig. 28 Prostate cancer market estimates and forecast, 2018-2030 (USD Million)
Fig. 29 Liver cancer market estimates and forecast, 2018-2030 (USD Million)
Fig. 30 Renal cell carcinoma market estimates and forecast, 2018-2030 (USD Million)
Fig. 31 Others market estimates and forecast, 2018-2030 (USD Million)
Fig. 32 Cellular immunotherapy market: End Use outlook and key takeaways
Fig. 33 Cellular immunotherapy market: End use movement analysis & market share 2021 & 2030
Fig. 34 Hospitals market estimates and forecast, 2018-2030 (USD Million)
Fig. 35 Cancer institutes end use market estimates and forecast, 2018-2030 (USD Million)
Fig. 36 Others end use market estimates and forecast, 2018-2030 (USD Million)
Fig. 37 Cellular immunotherapy: Regional outlook and key takeaways
Fig. 38 Regional outlook, 2021 & 2030
Fig. 39 North America
Fig. 40 North America market estimates and forecast, 2018-2030 (USD Million)
Fig. 41 U.S.
Fig. 42 U.S. market estimates and forecast, 2018-2030 (USD Million)
Fig. 43 Canada
Fig. 44 Canada market estimates and forecast, 2018-2030 (USD Million)
Fig. 45 Europe
Fig. 46 Europe market estimates and forecast, 2018-2030 (USD Million)
Fig. 47 U.K.
Fig. 48 U.K. market estimates and forecast, 2018-2030 (USD Million)
Fig. 49 Germany
Fig. 50 Germany market estimates and forecast, 2018-2030 (USD Million)
Fig. 51 France
Fig. 52 France market estimates and forecast, 2018-2030 (USD Million)
Fig. 53 Italy
Fig. 54 Italy market estimates and forecast, 2018-2030 (USD Million)
Fig. 55 Spain
Fig. 56 Spain market estimates and forecast, 2018-2030 (USD Million)
Fig. 57 Russia
Fig. 58 Russia market estimates and forecast, 2018-2030 (USD Million)
Fig. 59 Asia-Pacific
Fig. 60 Asia-Pacific market estimates and forecast, 2018-2030 (USD Million)
Fig. 61 Japan
Fig. 62 Japan market estimates and forecast, 2018-2030(USD Million)
Fig. 63 China
Fig. 64 China market estimates and forecast, 2018-2030 (USD Million)
Fig. 65 India
Fig. 66 India market estimates and forecast, 2018-2030 (USD Million)
Fig. 67 South Korea
Fig. 68 South Korea market estimates and forecast, 2018-2030 (USD Million)
Fig. 69 Australia
Fig. 70 Australia market estimates and forecast, 2018-2030 (USD Million)
Fig. 71 Latin America
Fig. 72 Latin America market estimates and forecast, 2018-2030 (USD Million)
Fig. 73 Brazil
Fig. 74 Brazil market estimates and forecast, 2018-2030 (USD Million)
Fig. 75 Mexico
Fig. 76 Mexico market estimates and forecast, 2018-2030 (USD Million)
Fig. 77 Argentina
Fig. 78 Argentina market estimates and forecast, 2018-2030 (USD Million)
Fig. 79 Middle East & Africa
Fig. 80 MEA market estimates and forecast, 2018-2030 (USD Million)
Fig. 81 South Africa
Fig. 82 South Africa market estimates and forecast, 2018-2030 (USD Million)
Fig. 83 Saudi Arabia
Fig. 84 Saudi Arabia market estimates and forecast, 2018-2030 (USD Million)
Fig. 85 UAE
Fig. 86 UAE market estimates and forecast, 2018-2030 (USD Million)
Fig. 87 Market differentiators
Fig. 88 Key company market share analysis, 2021
Fig. 89 Company market position analysis
Fig. 90 Competitive dashboard analysis
Fig. 91 Regional network map

Companies Mentioned

  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Merck KGaA
  • GlaxoSmithKline plc.
  • AstraZeneca
  • Pfizer Inc.
  • Gilead Sciences Inc. (Kite Pharma)
  • Dendreon Pharmaceuticals LLC
  • Novartis AG
  • Celyad
  • Adicet Bio, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages165
PublishedJuly 2022
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 7.5 Billion
Forecasted Market Value ( USD ) by 2030 $ 37.97 Billion
Compound Annual Growth Rate22.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Cellular Immunotherapy Market by Type, Indication, Technology Type, End-Use - Global Forecast 2025-2030 - Product Image

Cellular Immunotherapy Market by Type, Indication, Technology Type, End-Use - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Cancer Gene Therapy Market Size, Share & Trends Analysis Report By Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy), By End-use (Research Institutes, Biopharmaceutical Companies), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Cancer Gene Therapy Market Size, Share & Trends Analysis Report By Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy), By End-use (Research Institutes, Biopharmaceutical Companies), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 120 Pages
  • Global
From
T-Cell Immunotherapy Market by Mechanism Of Action, Product Class, Type of Therapy, Indication - Global Forecast 2025-2030 - Product Image

T-Cell Immunotherapy Market by Mechanism Of Action, Product Class, Type of Therapy, Indication - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Cellular Immunotherapy Global Market Report 2024 - Product Image

Cellular Immunotherapy Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Head And Neck Cancer Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (Chemotherapy, Immunotherapy), By Route Of Administration (Injectable, Oral), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Head And Neck Cancer Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (Chemotherapy, Immunotherapy), By Route Of Administration (Injectable, Oral), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.